Context Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2024, on November 6, 2024. The company announced cash and cash equivalents of $84.8 million as of September 30, 2024. Management expects this cash position to fund operations into 2027, covering the estimated duration of the dose escalation portions of its CTIM-76 and CT-95 Phase 1 trials, and expenses through the IND filing for CT-202.
During the quarter, Context expanded its pipeline of T cell engaging bispecific antibodies through the acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. The company continues to activate additional sites for its Phase 1 trial for CTIM-76 and expects to dose its first patient by the end of 2024. The first patient in the CT-95 Phase 1 study is expected to be enrolled in the first quarter of 2025.
Context also strengthened its Board of Directors with the appointments of Dr. Karen Smith and Dr. Luke Walker. These additions are part of the company's transformation, bringing diversified skillsets and operational experience to guide Context through its next stages of growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.